NCT04977024View on ClinicalTrials.gov

SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

September 27, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
COVID-19 InfectionHematopoietic and Lymphoid System NeoplasmLeukemiaLymphomaPlasma Cell Myeloma
Interventions
BIOLOGICAL

COVID-19 Vaccine

Receive SOC mRNA SARS-CoV-2 vaccine IM

OTHER

Diagnostic Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1

Given IM

Trial Locations (6)

11794

RECRUITING

SUNY-Stony Brook, Stony Brook

21205

RECRUITING

Johns Hopkins University, Baltimore

27157

RECRUITING

Atrium Health Wake Forest Baptist, Winston-Salem

91010

ACTIVE_NOT_RECRUITING

City of Hope Medical Center, Duarte

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

01655

RECRUITING

U Mass Chan Medical School, Worcester

All Listed Sponsors
lead

GeoVax, Inc.

INDUSTRY